Abstract
Objective Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. Methods Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies. Clinical symptoms and relapse proportions were compared among these clusters. Results Sixty-one patients were enrolled in this study: 28 were diagnosed with PM, and 33 were diagnosed with DM. The following 3 clusters were determined: 1 (n = 10), anti-Jo-1 and anti-SS-A/Ro-52 antibodies double positive (10/10, 100%); 2 (n = 24), anti-SS-A/Ro-52 antibody positive (20/24, 83%), anti-Jo-1 antibody negative (24/24, 100%), and anti-ARS antibodies (excluding anti-Jo-1 antibody) positive (15/24, 63%); and 3 (n = 27), anti-Jo-1 and anti-SS-A/Ro52 antibodies double negative (26/27, 96%). The proportion of patients who relapsed was significantly lower in cluster 3 than it was in clusters 1 and 2 (risk ratio, 0.37; 95% confidence interval, 0.17-0.83; p = 0.026 and risk ratio, 0.42; 95% confidence interval, 0.20-0.89; P = 0.019, respectively). There was no difference in the proportion of relapsed patients between clusters 1 and 2. Conclusions Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 246-251 |
| Number of pages | 6 |
| Journal | Journal of Clinical Rheumatology |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Sep 1 2019 |
Fingerprint
Keywords
- cluster analysis
- dermatomyositis
- line immunoassay
- polymyositis
ASJC Scopus subject areas
- Rheumatology
Cite this
Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients with Polymyositis/Dermatomyositis. / Ohashi, Keiji; Sada, Kenei; Nakai, Yu; Matsushima, Shun; Asano, Yosuke; Hayashi, Keigo; Yamamura, Yuriko; Hiramatsu, Sumie; Miyawaki, Yoshia; Morishita, Michiko; Katsuyama, Takayuki; Katsuyama, Eri; Watanabe, Haruki; Tatebe, Noriko; Narazaki, Mariko; Matsumoto, Yoshinori; Sunahori Watanabe, Katsue; Kawabata, Tomoko; Wada, Jun.
In: Journal of Clinical Rheumatology, Vol. 25, No. 6, 01.09.2019, p. 246-251.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients with Polymyositis/Dermatomyositis
AU - Ohashi, Keiji
AU - Sada, Kenei
AU - Nakai, Yu
AU - Matsushima, Shun
AU - Asano, Yosuke
AU - Hayashi, Keigo
AU - Yamamura, Yuriko
AU - Hiramatsu, Sumie
AU - Miyawaki, Yoshia
AU - Morishita, Michiko
AU - Katsuyama, Takayuki
AU - Katsuyama, Eri
AU - Watanabe, Haruki
AU - Tatebe, Noriko
AU - Narazaki, Mariko
AU - Matsumoto, Yoshinori
AU - Sunahori Watanabe, Katsue
AU - Kawabata, Tomoko
AU - Wada, Jun
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objective Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. Methods Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies. Clinical symptoms and relapse proportions were compared among these clusters. Results Sixty-one patients were enrolled in this study: 28 were diagnosed with PM, and 33 were diagnosed with DM. The following 3 clusters were determined: 1 (n = 10), anti-Jo-1 and anti-SS-A/Ro-52 antibodies double positive (10/10, 100%); 2 (n = 24), anti-SS-A/Ro-52 antibody positive (20/24, 83%), anti-Jo-1 antibody negative (24/24, 100%), and anti-ARS antibodies (excluding anti-Jo-1 antibody) positive (15/24, 63%); and 3 (n = 27), anti-Jo-1 and anti-SS-A/Ro52 antibodies double negative (26/27, 96%). The proportion of patients who relapsed was significantly lower in cluster 3 than it was in clusters 1 and 2 (risk ratio, 0.37; 95% confidence interval, 0.17-0.83; p = 0.026 and risk ratio, 0.42; 95% confidence interval, 0.20-0.89; P = 0.019, respectively). There was no difference in the proportion of relapsed patients between clusters 1 and 2. Conclusions Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.
AB - Objective Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. Methods Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies. Clinical symptoms and relapse proportions were compared among these clusters. Results Sixty-one patients were enrolled in this study: 28 were diagnosed with PM, and 33 were diagnosed with DM. The following 3 clusters were determined: 1 (n = 10), anti-Jo-1 and anti-SS-A/Ro-52 antibodies double positive (10/10, 100%); 2 (n = 24), anti-SS-A/Ro-52 antibody positive (20/24, 83%), anti-Jo-1 antibody negative (24/24, 100%), and anti-ARS antibodies (excluding anti-Jo-1 antibody) positive (15/24, 63%); and 3 (n = 27), anti-Jo-1 and anti-SS-A/Ro52 antibodies double negative (26/27, 96%). The proportion of patients who relapsed was significantly lower in cluster 3 than it was in clusters 1 and 2 (risk ratio, 0.37; 95% confidence interval, 0.17-0.83; p = 0.026 and risk ratio, 0.42; 95% confidence interval, 0.20-0.89; P = 0.019, respectively). There was no difference in the proportion of relapsed patients between clusters 1 and 2. Conclusions Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.
KW - cluster analysis
KW - dermatomyositis
KW - line immunoassay
KW - polymyositis
UR - http://www.scopus.com/inward/record.url?scp=85071376210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071376210&partnerID=8YFLogxK
U2 - 10.1097/RHU.0000000000000836
DO - 10.1097/RHU.0000000000000836
M3 - Article
C2 - 29933322
AN - SCOPUS:85071376210
VL - 25
SP - 246
EP - 251
JO - Journal of Clinical Rheumatology
JF - Journal of Clinical Rheumatology
SN - 1076-1608
IS - 6
ER -